Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by TechOneon Jan 21, 2025 1:55pm
110 Views
Post# 36413783

Spectral on Linkedin Today

Spectral on Linkedin Today Did you know?

The timing of sepsis diagnosis may significantly impact healthcare costs and patient outcomes. A study of over 2.5 million sepsis cases in the U.S. revealed:

Average cost per case:
- Sepsis diagnosed at admission (Present on Admission, POA): $18,023
- Sepsis diagnosed after admission (Not POA): $51,022

Mortality rates by severity and POA status:
Non-POA cases:
- Sepsis without organ dysfunction: 13.8%
- Severe sepsis: 30.7%
- Septic shock: 48.5%

POA cases:
- Sepsis without organ dysfunction: 4.5%
- Severe sepsis: 12.9%
- Septic shock: 31.2%

Improving early identification of sepsis could reduce both costs and mortality, highlighting the urgent need for better diagnostic tools and protocols.
<< Previous
Bullboard Posts
Next >>